Myxoma virus virotherapy for glioma in immunocompetent animal models

Optimizing administration routes and synergy with rapamycin

Xue Qing Lun, Tommy Alain, Franz J. Zemp, Hongyuan Zhou, Masmudur Rahman, Mark G. Hamilton, Douglas McFadden, John Bell, Donna L. Senger, Peter A. Forsyth

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Oncolytic myxoma virus (MYXV) is being developed as a novel virotherapeutic against human brain cancer and has promising activity against human brain tumor models in immunocompromised hosts. Because an intact immune system could reduce its efficacy, the purpose of this study was to evaluate the oncolytic potential of MYXV in immunocompetent racine glioma models. Here, we report that MYXV infects and kills all racine cell glioma lines and that its effects are enhanced by rapamycin. Intratumoral administration of MYXV with rapamycin improved viral replication in the tumor and significantly prolonged host survival. Similarly, coadministration via a method of convection-enhanced delivery (CED) enhanced viral replication and efficacy in vivo. Mechanisms by which rapamycin improved MYXV oncolysis included an inhibition of type I IFN production in vitro and a reduction of intratumoral infiltration of CD68+ microglia/macrophages and CD163+ macrophages in vivo. Our findings define a method to improve MYXV efficacy against gliomas by rapamycin coadministration, which acts to promote immune responses engaged by viral delivery.

Original languageEnglish (US)
Pages (from-to)598-608
Number of pages11
JournalCancer Research
Volume70
Issue number2
DOIs
StatePublished - Jan 15 2010
Externally publishedYes

Fingerprint

Myxoma virus
Sirolimus
Glioma
Animal Models
Brain Neoplasms
Macrophages
Oncolytic Viruses
Convection
Immunocompromised Host
Microglia
Human Activities
Immune System
Cell Line
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Myxoma virus virotherapy for glioma in immunocompetent animal models : Optimizing administration routes and synergy with rapamycin. / Lun, Xue Qing; Alain, Tommy; Zemp, Franz J.; Zhou, Hongyuan; Rahman, Masmudur; Hamilton, Mark G.; McFadden, Douglas; Bell, John; Senger, Donna L.; Forsyth, Peter A.

In: Cancer Research, Vol. 70, No. 2, 15.01.2010, p. 598-608.

Research output: Contribution to journalArticle

Lun, Xue Qing ; Alain, Tommy ; Zemp, Franz J. ; Zhou, Hongyuan ; Rahman, Masmudur ; Hamilton, Mark G. ; McFadden, Douglas ; Bell, John ; Senger, Donna L. ; Forsyth, Peter A. / Myxoma virus virotherapy for glioma in immunocompetent animal models : Optimizing administration routes and synergy with rapamycin. In: Cancer Research. 2010 ; Vol. 70, No. 2. pp. 598-608.
@article{96e9716b4a1b42d686e84afc304ba16a,
title = "Myxoma virus virotherapy for glioma in immunocompetent animal models: Optimizing administration routes and synergy with rapamycin",
abstract = "Oncolytic myxoma virus (MYXV) is being developed as a novel virotherapeutic against human brain cancer and has promising activity against human brain tumor models in immunocompromised hosts. Because an intact immune system could reduce its efficacy, the purpose of this study was to evaluate the oncolytic potential of MYXV in immunocompetent racine glioma models. Here, we report that MYXV infects and kills all racine cell glioma lines and that its effects are enhanced by rapamycin. Intratumoral administration of MYXV with rapamycin improved viral replication in the tumor and significantly prolonged host survival. Similarly, coadministration via a method of convection-enhanced delivery (CED) enhanced viral replication and efficacy in vivo. Mechanisms by which rapamycin improved MYXV oncolysis included an inhibition of type I IFN production in vitro and a reduction of intratumoral infiltration of CD68+ microglia/macrophages and CD163+ macrophages in vivo. Our findings define a method to improve MYXV efficacy against gliomas by rapamycin coadministration, which acts to promote immune responses engaged by viral delivery.",
author = "Lun, {Xue Qing} and Tommy Alain and Zemp, {Franz J.} and Hongyuan Zhou and Masmudur Rahman and Hamilton, {Mark G.} and Douglas McFadden and John Bell and Senger, {Donna L.} and Forsyth, {Peter A.}",
year = "2010",
month = "1",
day = "15",
doi = "10.1158/0008-5472.CAN-09-1510",
language = "English (US)",
volume = "70",
pages = "598--608",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Myxoma virus virotherapy for glioma in immunocompetent animal models

T2 - Optimizing administration routes and synergy with rapamycin

AU - Lun, Xue Qing

AU - Alain, Tommy

AU - Zemp, Franz J.

AU - Zhou, Hongyuan

AU - Rahman, Masmudur

AU - Hamilton, Mark G.

AU - McFadden, Douglas

AU - Bell, John

AU - Senger, Donna L.

AU - Forsyth, Peter A.

PY - 2010/1/15

Y1 - 2010/1/15

N2 - Oncolytic myxoma virus (MYXV) is being developed as a novel virotherapeutic against human brain cancer and has promising activity against human brain tumor models in immunocompromised hosts. Because an intact immune system could reduce its efficacy, the purpose of this study was to evaluate the oncolytic potential of MYXV in immunocompetent racine glioma models. Here, we report that MYXV infects and kills all racine cell glioma lines and that its effects are enhanced by rapamycin. Intratumoral administration of MYXV with rapamycin improved viral replication in the tumor and significantly prolonged host survival. Similarly, coadministration via a method of convection-enhanced delivery (CED) enhanced viral replication and efficacy in vivo. Mechanisms by which rapamycin improved MYXV oncolysis included an inhibition of type I IFN production in vitro and a reduction of intratumoral infiltration of CD68+ microglia/macrophages and CD163+ macrophages in vivo. Our findings define a method to improve MYXV efficacy against gliomas by rapamycin coadministration, which acts to promote immune responses engaged by viral delivery.

AB - Oncolytic myxoma virus (MYXV) is being developed as a novel virotherapeutic against human brain cancer and has promising activity against human brain tumor models in immunocompromised hosts. Because an intact immune system could reduce its efficacy, the purpose of this study was to evaluate the oncolytic potential of MYXV in immunocompetent racine glioma models. Here, we report that MYXV infects and kills all racine cell glioma lines and that its effects are enhanced by rapamycin. Intratumoral administration of MYXV with rapamycin improved viral replication in the tumor and significantly prolonged host survival. Similarly, coadministration via a method of convection-enhanced delivery (CED) enhanced viral replication and efficacy in vivo. Mechanisms by which rapamycin improved MYXV oncolysis included an inhibition of type I IFN production in vitro and a reduction of intratumoral infiltration of CD68+ microglia/macrophages and CD163+ macrophages in vivo. Our findings define a method to improve MYXV efficacy against gliomas by rapamycin coadministration, which acts to promote immune responses engaged by viral delivery.

UR - http://www.scopus.com/inward/record.url?scp=76549086994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76549086994&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-09-1510

DO - 10.1158/0008-5472.CAN-09-1510

M3 - Article

VL - 70

SP - 598

EP - 608

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 2

ER -